Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with primary advanced or recurrent endometrial cancer; use with carboplatin and paclitaxel followed by single-agent dostarlimab.
LAMPGEN ANALYSIS
Why it matters
The label expanded from dMMR or MSI-high disease to a broader endometrial cancer population.
What research teams should watch
Continue recording MMR status for subgroup interpretation and verify the switch from combination to maintenance dosing.
PRIMARY RECORDS